Crinetics Pharmaceuticals

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Crinetics Pharmaceuticals, established in 2008 and headquartered in United States, North America., specializes in Early Stage Venture investments across Health Care, Pharmaceutical, Medical, Therapeutics, Oncology, Venture Capital, Finance, Biotechnology, Life Science, AgTech. Their recent investments include Radionetics Oncology, 5AM Ventures, DCVC Bio, GordonMD Global Investments. The highest investment round they participated in was $9.0B. Among their most notable exits are Radionetics Oncology and 5AM Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.